Septerna (NASDAQ:SEPN) Given “Overweight” Rating at Cantor Fitzgerald

Septerna (NASDAQ:SEPN)‘s stock had its “overweight” rating reiterated by Cantor Fitzgerald in a research report issued on Tuesday,Benzinga reports. They currently have a $50.00 price objective on the stock. Cantor Fitzgerald’s price target would suggest a potential upside of 304.56% from the stock’s current price.

Several other equities research analysts have also recently issued reports on SEPN. Wells Fargo & Company started coverage on shares of Septerna in a research report on Tuesday, November 19th. They issued an “overweight” rating and a $43.00 target price on the stock. JPMorgan Chase & Co. began coverage on shares of Septerna in a research note on Tuesday, November 19th. They set an “overweight” rating and a $38.00 price objective for the company. Finally, TD Cowen assumed coverage on Septerna in a report on Tuesday, November 19th. They issued a “buy” rating on the stock.

Septerna Price Performance

Shares of Septerna stock traded down $0.81 during mid-day trading on Tuesday, hitting $12.36. 7,048 shares of the stock were exchanged, compared to its average volume of 220,729. The stock has a 50-day moving average of $20.46. Septerna has a twelve month low of $11.77 and a twelve month high of $28.99.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of SEPN. Charles Schwab Investment Management Inc. acquired a new position in Septerna during the 4th quarter worth approximately $3,197,000. Bank of New York Mellon Corp purchased a new stake in shares of Septerna during the fourth quarter valued at approximately $872,000. Lindbrook Capital LLC acquired a new position in shares of Septerna during the fourth quarter worth $481,000. Rhumbline Advisers purchased a new position in shares of Septerna in the fourth quarter valued at $458,000. Finally, M&T Bank Corp acquired a new stake in Septerna during the 4th quarter valued at $376,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.